AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02622321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: Participants will continue to receive rFVIIa.
Study NCT02622321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa
Description: Participants will continue to receive rFVIIa.
Study NCT02549027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
Study NCT02622321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPCC
Description: Participants will continue to receive aPCC.
Study NCT02622321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aPCC
Description: Participants will continue to receive aPCC.
Study NCT02385591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Support
Description: Telephone-based physical activity advice and support delivered by SMS.
Study NCT00965718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated T lymphocyte
Description: Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
Study NCT01634360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
Study NCT02892071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 22% TCA peel
Description: One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
Study NCT02892071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser
Description: One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
Study NCT02892071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Qs-NdYag laser
Description: Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
Study NCT02052674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vented urinary drainage system
Description: This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
Study NCT02052674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-vented urinary drainage system
Description: This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
Study NCT03660267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine coffee
Description: drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine
Study NCT03660267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decaffiene coffee
Description: drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine
Study NCT03660267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: still water
Description: drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine
Study NCT03740061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle
Study NCT05422833 — intervention group
Intervention type: OTHER
Intervention: Evaluation and analysis of clinical data
Description: Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
Study NCT01462422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
Study NCT01462422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
Study NCT01950507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Entocort EC 3 mg given orally three times daily for at least 14 days
Study NCT01950507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 400 mg orally once daily for CrCl greater than or equal to 50 ml/min
Study NCT01950507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
Study NCT01950507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
Study NCT00646776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: Capsule, Oral, 150 mg, once daily, 11 Days
Study NCT00646776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin + Atazanavir + Ritonavir
Description: Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)
Study NCT02949102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crave Crush
Description: Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
Study NCT02949102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
Study NCT03919214 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Automated Messaging
Description: This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg.
Study NCT05219214 — intervention group
Intervention type: OTHER
Intervention: Chinese medicine
Description: There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
Study NCT04802278 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Any COVID-19 vaccine
Study NCT00912639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel loaded Polymeric micelle
Description: Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
Study NCT03523806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solution-Focused Coaching in Pediatric Rehabilitation
Description: A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
Study NCT03725098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows
Description: The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
Study NCT03725098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLOSEAL
Description: The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
Study NCT04147130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MultiPAP Plus
Description: Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
Study NCT04147130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will receive the usual clinical care based on current clinical practice guidelines.
Study NCT04147130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive the usual clinical care based on current clinical practice guidelines.
Study NCT03485547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
Study NCT01603004 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
Study NCT03700671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
Study NCT03700671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training
Description: The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
Study NCT03812094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enurad 400
Description: Alarm treatment
Study NCT03812094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Bladder advice
Description: Pre-specified Basic bladder advice
Study NCT02323113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.
Study NCT02860013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Study NCT00160485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: dosage required to obtain adequate glucose control
Study NCT00160485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: variable dosage to obtain glucose control
Study NCT03724760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized repeated feedback approach
Description: Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
Study NCT02007694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
Study NCT02007694 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
Study NCT04352647 — intervention group
Intervention type: BEHAVIORAL
Intervention: female athletes
Description: The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
Study NCT02704117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magentic Stimulation
Description: This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
Study NCT01655615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventure programme
Description: The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
Study NCT02562053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Women will receive oral fluoxetine 20 mg daily.
Study NCT02562053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 single dose
Description: GLPG3067 oral suspension, single ascending doses, daily
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Placebo, oral suspension, daily
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 multiple dose
Description: GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple dose
Description: Placebo, oral suspension, daily for 14 days
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral suspension
Description: GLPG3067 oral suspension, single dose, daily
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral tablet
Description: GLPG3067 oral tablet, single dose, daily
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067/GLPG2222 multiple dose
Description: GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
Study NCT04182399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zonisamide Capsules
Description: anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
Study NCT04604886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising
Description: Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
Study NCT04604886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dobutamine stress test
Description: Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
Study NCT03696238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg of Aronox® >40% polyphenol aronia extract
Description: Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
Study NCT03696238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
Study NCT01837446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% morphine solution
Study NCT01837446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium aluminum hydroxide
Study NCT01837446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% viscous lidocaine
Study NCT01837446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Study NCT02748044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CC-Cruiser
Description: An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
Study NCT04346173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: furlow z plasty with buccinator myomucosal flap
Description: using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
Study NCT01396824 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04380194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nano-composite screening
Description: Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
Study NCT00616018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 4 g/day for 10 consecutive days
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG3067/GLPG2222 Placebo multiple dose
Description: GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067/GLPG2222/GLPG2737 multiple dose
Description: GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
Study NCT03128606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
Description: GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
Study NCT01203111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
Study NCT01203111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal